You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR SODIUM BENZOATE; SODIUM PHENYLACETATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SODIUM BENZOATE; SODIUM PHENYLACETATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed Johns Hopkins University Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed National Center for Research Resources (NCRR) Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00597909 ↗ Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy Terminated Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 2 2007-12-01 The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
NCT00977600 ↗ A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) Completed Ucyclyd Pharma, Inc. Phase 1 2005-03-01 To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.
NCT00977600 ↗ A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 1 2005-03-01 To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.
NCT04155567 ↗ A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants Completed Takeda Phase 1 2019-11-13 The purpose of this study is to evaluate the PK, safety and tolerability of phenylacetate and benzoate after intravenous administration of TAK-123 in Japanese healthy adult male participants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SODIUM BENZOATE; SODIUM PHENYLACETATE

Condition Name

Condition Name for SODIUM BENZOATE; SODIUM PHENYLACETATE
Intervention Trials
Amino Acid Metabolism, Inborn Errors 1
Healthy 1
Healthy Volunteers 1
Hepatic Encephalopathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SODIUM BENZOATE; SODIUM PHENYLACETATE
Intervention Trials
Metabolism, Inborn Errors 1
Amino Acid Metabolism, Inborn Errors 1
Hepatic Encephalopathy 1
Brain Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SODIUM BENZOATE; SODIUM PHENYLACETATE

Trials by Country

Trials by Country for SODIUM BENZOATE; SODIUM PHENYLACETATE
Location Trials
United States 2
Ukraine 1
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SODIUM BENZOATE; SODIUM PHENYLACETATE
Location Trials
Texas 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SODIUM BENZOATE; SODIUM PHENYLACETATE

Clinical Trial Phase

Clinical Trial Phase for SODIUM BENZOATE; SODIUM PHENYLACETATE
Clinical Trial Phase Trials
Phase 2 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SODIUM BENZOATE; SODIUM PHENYLACETATE
Clinical Trial Phase Trials
Completed 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SODIUM BENZOATE; SODIUM PHENYLACETATE

Sponsor Name

Sponsor Name for SODIUM BENZOATE; SODIUM PHENYLACETATE
Sponsor Trials
Horizon Pharma Ireland, Ltd., Dublin Ireland 2
Johns Hopkins University 1
National Center for Research Resources (NCRR) 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SODIUM BENZOATE; SODIUM PHENYLACETATE
Sponsor Trials
Industry 3
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.